Evidence map›Paper›PMID 40114604›Full record

ArticleNanomedicine (London, England)2025

Selenium nanoparticles attenuate retinal pathological angiogenesis by disrupting cell cycle distribution.

Zheng Nie, Yongxuan Liu, Li Xu, Yang Wang, Mengzhu Wang, Wen Zhou, Huimin Zhu, Min Zhao, Shikun Wang, Hongjian Zhang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Recent Progress in Selenium Nanomedicines for Ocular Diseases.International journal of nanomedicine · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zheng NieDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Yongxuan LiuDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Li XuDepartment of Laboratory Diagnosis, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Yang WangDepartment of Reproductive Medicine Center, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Mengzhu WangDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Wen ZhouDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Huimin ZhuDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Min ZhaoDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Shikun WangDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Hongjian ZhangOriental Pan-Vascular Devices Innovation College, University of Shanghai for Science and Technology, Shanghai, China.
Meijing GengOriental Pan-Vascular Devices Innovation College, University of Shanghai for Science and Technology, Shanghai, China.
Mai PengDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Hao ZengDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Yuan ZhangDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
Pengxi ZhuShanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
Wei ShenDepartment of Ophthalmology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aims to explore the mechanism by which selenium nanoparticles (SeNPs) inhibit retinal neovascularization (RNV) and to identify a more effective treatment for pathological RNV. MATERIALS &

methodsThe characterization and identification of the synthesized selenium nanoparticles (SeNPs) were conducted to investigate their effects on the function of human umbilical vein endothelial cells (HUVECs), retinal blood vessel development in mice, and the impact on oxygen-induced retinopathy. Tritium-labeled thymine was utilized to label newly synthesized DNA both

resultsSeNPs can significantly inhibit the functions of vascular endothelial cells, particularly their proliferation, both

conclusionSeNPs may be a novel treatment for the interference of retinal neovascularization.

Indexed as

Cell CycleNanoparticlesRetinal NeovascularizationSeleniumAnimalsCell ProliferationHumansHuman Umbilical Vein Endothelial CellsMaleMiceMice, Inbred C57BLRetinaRetinal VesselsSeleniumangiogenesisoxygen-induced retinopathyretinal neovascularizationSelenium nanoparticlesthe cell cycle

Identifiers

PMID40114604
PMCPMC11988272

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.